PhaSER Biomedical is a Dundee-headquartered company located in the University Innovation Hub, formed in October 2022 to develop humanised preclinical models for drug development. Its mission is to accelerate the development and use of safer new drugs and to develop computational models that predict the risk of adverse drug reactions in patients on polypharmacy. It combines human-relevant preclinical humanised and knock out models with specialist expertise in drug metabolism, pharmacokinetics, bioanalysis and mathematical modelling study design.
PhaSER Biomedical: Venture Capital Funding History
PhaSER Biomedical
PhaSER Biomedical
- Life Sciences
- Dundee, United Kingdom
- £2m
- phaserbio.com
- Update Information
More venture news
- 9 Nov 2026

PhaSER BiomedicalPhaSER Biomedical secures a £2m grant from Gates Foundation to discover new treatments for neglected diseases
GrantLife Sciences - 5 Nov 2026

Alethio TherapeuticsAlethio Therapeutics secures a £67m Series A round led by Sofinnova Partners and RA Capital to develop targeted blood cancer therapies
Series ALife Sciences - 5 Nov 2026

Potential SciencesPotential Sciences launches from stealth with an eight figure investment led by UK Sovereign AI Fund and Twin Path Ventures for its frontier lab for chemistry
EquityLife Sciences